Other languages Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Market Closed - Euronext Bruxelles Other stock markets 11:35:01 2024-04-23 am EDT			5-day change	1st Jan Change
11.7 ^EUR	-2.09%		-2.50%	-8.24%

Mar. 14	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
Mar. 14	Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Degroof Petercam verhoogt koersdoel Hyloris Pharma	Apr. 05
KBC Securities verhoogt koersdoel Hyloris	Mar. 27
Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	Mar. 14
Meer omzet maar ook groter verlies voor Hyloris	Mar. 14
Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives	Mar. 14
Communiqué à la requête de la FSMA sur les transactions avec QliniQ	Mar. 14
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024	Mar. 08
Hyloris Pharmaceuticals: le Maxigesic IV commercialisé aux Etats-unis	Feb. 28
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada	Feb. 28
Hyloris lanceert Maxigesic IV in de VS	Feb. 27
Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada	Feb. 27
Hyloris van start met Fase 3 studie	Feb. 14
Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires	Feb. 14
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	Feb. 14
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	Feb. 06
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	Feb. 05
Kepler Cheuvreux verhoogt koersdoel Hyloris	Jan. 31
Hyloris :remporte un succès contre la candidose vulvovaginale	Jan. 30
Hyloris presenteert positieve studieresultaten	Jan. 30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Other languages

Filters